Current Development of Monoclonal Antibodies in Cancer Therapy

• Published in: Recent results in cancer research Vol. 214; p. 1
• Main Authors: Parakh, Sagun, King, Dylan, Gan, Hui K, Scott, Andrew M
• Format: Journal Article
• Language: English
• Published: Germany 2020
• Subjects: Antibodies, Monoclonal - pharmacology; Clinical Trials as Topic; Humans; Immunotherapy; Neoplasms - therapy
• ISSN: 0080-0015
• DOI: 10.1007/978-3-030-23765-3_1

Exploiting the unique specificity of monoclonal antibodies has revolutionized the treatment and diagnosis of haematological and solid organ malignancies; bringing benefit to millions of patients over the past decades. Recent achievements include conjugating antibodies with toxic payloads resulting in superior efficacy and/or reduced toxicity, development of molecular imaging techniques targeting specific antigens for use as predictive and prognostic biomarkers, the development of novel bi- and tri-specific antibodies to enhance therapeutic benefit and abrogate resistance and the success of immunotherapy agents. In this chapter, we review an overview of antibody structure and function relevant to cancer therapy and provide an overview of pivotal clinical trials which have led to regulatory approval of monoclonal antibodies in cancer treatment. We further discuss resistance mechanisms and the unique side effects of each class of antibody and provide an overview of emerging therapeutic agents.